Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes

Keyphrases

• Type 2 Diabetic Patients 100%
• Fast-acting Insulin Aspart 100%
• Postprandial Glucose Control 100%
• Insulin Lispro 100%
• Biphasic Insulin 100%
• BIAsp 30 100%
• Biphasic Human Insulin 100%
• Type 2 Diabetes Mellitus (T2DM) 42%
• Blood Glucose 42%
• Aspartate 42%
• Lispro 42%
• Glucose Excursion 28%
• Cmax 28%
• Test Meal 28%
• Insulin-treated 28%
• Late Diabetic Complications 14%
• Glucose Concentration 14%
• Rapid-acting Insulin 14%
• Serum Insulin 14%
• Insulin Concentration 14%
• Post-meal 14%
• NPH Insulin 14%
• Glucose Control 14%
• Regular Insulin 14%
• Biphasic Human Insulin 30 14%

Nursing and Health Professions

• Insulin Aspart 100%
• Patient with Type 2 Diabetes 100%
• Recombinant Human Insulin 100%
• Human Insulin 100%
• Biphasic Insulin 100%
• Insulin Lispro 100%
• Glucose Blood Level 60%
• Non Insulin Dependent Diabetes Mellitus 60%
• Diabetic Complication 20%
• Insulin Derivative 20%
• Insulin Blood Level 20%
• Short Acting Insulin 20%
• Single Drug Dose 20%
• Pig Insulin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Insulin Aspart 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Recombinant Human Insulin 100%
• Human Insulin 100%
• Biphasic Insulin 100%
• Insulin Lispro 100%
• Insulin Analog 20%
• Diabetic Complication 20%
• Short Acting Insulin 20%
• NPH Insulin 20%
• Pig Insulin 20%